Golidocitinib favorable for relapsed/refractory T-cell lymphoma
Cancer
.
2024 Apr 15;130(8):1191-1192.
doi: 10.1002/cncr.35272.
Author
Mary Beth Nierengarten
PMID:
38498282
DOI:
10.1002/cncr.35272
No abstract available
Publication types
News
MeSH terms
Humans
Lymphoma, T-Cell* / drug therapy
Neoplasm Recurrence, Local* / drug therapy